RE:eight more sleepsThis is really attractive at this price.
The big question is if Hillary wins the election, will big money still stay away from medicine?
For Merus, if the company as a whole is performing decent, it's irrelevant in the long-term because their business is in Europe, their management is more prudent, and there isn't an issue with price gouging. There needs to be a news release from the company though that affirms investor confidence that they are different than Valeant/Concordia and performing well by most metrics.
Until then, I suspect the price will follow the trend.